A new treatment of renal anemia

Enarodustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI). It is an oral tablet for treating renal anemia and has independent intellectual property rights in major countries/regions around the world. This Product was developed by JAPAN TOBACCO INC., Japan, and filled a NDA in Japan in November 2019. In December 2019, Shenzhen Salubris Pharmaceuticals Co.,Ltd. signed an exclusive license agreement with JAPAN TOBACCO INC. for the development and commercialization in Mainland China, Hong Kong, Taiwan and Macao of Enarodustat. The "oxygen sensing mechanism" which Enarodustat is based on won the Nobel Prize in Physiology or Medicine in 2019.

latest news

Knowledge about renal anemia

Chronic kidney disease (CKD) has become an important public health problem in China, and anemia is one of the most common complications of CKD patients

Learn more

Project Progress

SAL951 project introduction

Learn more

How does the R&D team undertake the domestic landing of SAL951

Learn more